Highest-materiality recent filing
John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.
Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device
Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.
Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition
Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.
Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition
Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26
Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.
Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing
OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.
On May 8, 2025, Kathleen G. Weber notified OraSure Technologies, Inc. (the “Company”) of her resignation as Chief Product Officer of the Company, effective June 30, 2025.
the Board appointed John P. Kenny as a new member of the Board, with such appointment to be effective as of the Effective Date.
Max materiality 0.70 · Median 0.50 · Most common event earnings